Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neutra4: MAU868 for BK Viremia in Kidney Transplant
NCT04294472Phase 2Completed
- Sponsor
- Vera Therapeutics
- Start
- Aug 2020
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of traxivitug in BK virus infection (4 arms), sponsored by Vera Therapeutics. Primary endpoints: Time to Decrease of BKV Plasma Viral Load by 1 Log at Week 36 and Time to First Decrease of BKV Plasma Viral Load to Less Than Lower Limit of Quantification (LLOQ) at Week 36. Started Aug 2020; status: completed.
02
Drugs
traxivitug
03
Conditions
BK virus infection
Beyond the preview
Go deeper on NCT04294472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294472.